Literature DB >> 1913690

Androgen sensitivity of the new human breast cancer cell line MFM-223.

R Hackenberg1, S Lüttchens, J Hofmann, R Kunzmann, F Hölzel, K D Schulz.   

Abstract

The mammary carcinoma cell line MFM-223 is characterized by high androgen and low estrogen and progesterone receptor levels. With the dextran charcoal method, androgen binding was determined at 160 fmol/mg protein corresponding to approximately 100,000 binding sites per cell in whole cell binding assays. The estrogen and progesterone receptor contents were between 8 and 18 fmol/mg protein. The proliferation of MFM-223 cells was significantly inhibited by doses greater than 0.01 nM dihydrotestosterone. The androgenic inhibition of cell proliferation was antagonized by the antiandrogens cyproterone acetate and hydroxyflutamide. In spite of the low estrogen receptor content, MFM-223 cell proliferation was slightly enhanced by 10 nM 17 beta-estradiol. Treatment with 17 beta-estradiol or dihydrotestosterone failed to provoke an increase of the progesterone receptor level. MFM-223 cells have characteristic patterns of isoenzyme polymorphism and of karyotype alterations revealing marker chromosomes and homogeneously staining regions. In the spectrum of human mammary carcinoma cell lines, MFM-223 cells offer a unique model to investigate molecular mechanisms of androgen receptor action.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913690

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Androgen resistance in female mice increases susceptibility to DMBA-induced mammary tumors.

Authors:  Ulla Simanainen; Yan Ru Gao; Kirsty A Walters; Geoff Watson; Reena Desai; Mark Jimenez; David J Handelsman
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

Review 2.  Role of the androgen receptor in human breast cancer.

Authors:  S N Birrell; R E Hall; W D Tilley
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

3.  Human androgen receptor expressed in HeLa cells activates transcription in vitro.

Authors:  P De Vos; J Schmitt; G Verhoeven; H G Stunnenberg
Journal:  Nucleic Acids Res       Date:  1994-04-11       Impact factor: 16.971

4.  Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor.

Authors:  R Hackenberg; T Hawighorst; A Filmer; A H Nia; K D Schulz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 5.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

6.  Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells.

Authors:  J Hofmann; B Wegmann; R Hackenberg; R Kunzmann; K D Schulz; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription.

Authors:  Sook Shin; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

8.  Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells.

Authors:  M Di Monaco; E Brignardello; L Leonardi; V Gatto; G Boccuzzi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Role of KCNMA1 in breast cancer.

Authors:  Martin Oeggerli; Yuemin Tian; Christian Ruiz; Barbara Wijker; Guido Sauter; Ellen Obermann; Uwe Güth; Inti Zlobec; Matthias Sausbier; Karl Kunzelmann; Lukas Bubendorf
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

Review 10.  Obesity and Androgen Receptor Signaling: Associations and Potential Crosstalk in Breast Cancer Cells.

Authors:  Nelson Rangel; Victoria E Villegas; Milena Rondón-Lagos
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.